Produktinformation
Takinib is a small molecule that is being developed as a treatment for inflammatory bowel disease (IBD). Takinib inhibits the production of pro-inflammatory factors, including cytokines and chemokines. It also reduces the proliferation of cancer cells. Takinib has been shown to be effective in inhibiting cisplatin-induced nephrotoxicity in vivo. It has also been shown to inhibit angiogenesis by suppressing the expression of vascular endothelial growth factor (VEGF) and to induce apoptosis in activated T cells. The molecule also inhibits the expression of molecules such as tumor necrosis factor alpha (TNFα), interleukin 6 (IL6), and monocyte chemoattractant protein 1 (MCP1). The drug's effectiveness against IBD has been demonstrated in a number of clinical trials. The drug has an effective dose of 10mg/kg/day, which is administered orally for up to 12 weeks.
Chemische Eigenschaften
Technische Anfrage zu: 3D-LUB55637 Takinib
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.
